Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: A comparison with a cohort treated by radiotherapy alone

Gynecologic and Obstetric Investigation

Volumn 69, Issue 4, 2010, Pages 224-232

  Mabuchi, Seiji ^a   Ugaki, Hiromi ^a   Isohashi, Fumiaki ^a   Yoshioka, Yasuo ^a   Temma, Kumiko ^a   Yada Hashimoto, Namiko ^a   Takeda, Takashi ^a   Yamamoto, Toshiya ^a   Yoshino, Kiyoshi ^a   Nakajima, Ryuichi ^a   Kuragaki, Chie ^a   Morishige, Kenichirou ^a   Enomoto, Takayuki ^a   Inoue, Takehiro ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoradiotherapy; High dose rate intracavitary brachytherapy; Nedaplatin; Recurrence; Stage IIIb cervical cancer

Indexed keywords

NEDAPLATIN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LARGE INTESTINE PERFORATION; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RECTOVAGINAL FISTULA; THROMBOCYTOPENIA; TREATMENT FAILURE; UTERINE CERVIX CANCER;

AGED; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 73649145189     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000273207     Document Type: Article

References (38)

1. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the cervix uteri. Int J Gynaecol Obstet 2003; 83(suppl 1):41-78.
2. Stehman FB, Perez CA, Kurman RJ, et al: Uterine cervix; in Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynecology Oncology. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 841- 918.
3. Kovalic JJ, Perez CA, Grigsby PW, Lockett MA: The effect of volume of disease in patients with carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1991; 21: 905-910.
4. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke- Pearson DL, Liao SY: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1334-1335.
5. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137-1143.
6. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144-1153.
7. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 1154-1161.
8. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J Clin Oncol 2004; 22: 872-880. (Pubitemid 41103599)
9. Lee SK, Jones HW 3rd: Prognostic significance of ureteral obstruction in primary cervical cancer. Int J Gynaecol Obstet 1994; 44: 59-65.
10. Monk BJ, Alberts DS, Burger RA, Fanta PT, Hallum AV 3rd, Hatch KD, Salmon SE: In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254- S), with that of cisplatin and carboplatin against fresh, human cervical cancers. Gynecol Oncol 1998; 71: 308-312.
11. Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Ohmori T, Saijo N: Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother Pharmacol 1991; 27: 263-270.
12. Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J, Maruyama T: Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 2005; 79: 451-460.
13. Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M: Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 2005; 28: 1385-1388.
14. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N: Phase II study of (glycolate-O,O ) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990; 26: 393-396.
15. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K: An early phase II clinical study of cis -diammine glycolatoplatinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 1992; 19: 863-869.
16. Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y, Takeuchi S, Takamizawa H, Suzuki M, Arai M, Ota M, et al: Phase II study of 254-S ( cis -diammine glycolatoplatinum) for gynecological cancer. Gan To Kagaku Ryoho 1992; 19: 695-701.
17. Mabuchi S, Morishige K, Fujita M, Tsutsui T, Sakata M, Enomoto T, Kimura T: The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecl Oncol 2009; 113: 200-204.
18. Nakamura Y, Hasegawa M, Hayakawa K, Matsuura M, Suzuki Y, Nasu S, Yamakawa M, Mitsuhashi N, Niibe H: Induction of p53- dependent apoptosis in vivo by nedaplatin and ionizing radiation. Oncol Rep 2000; 7: 261-265.
19. Tanaka T, Yukawa K, Umesaki N: Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro. Eur J Gynaecol Oncol 2007; 28: 352-355.
20. Sato Y, Takayama T, Sagawa T, Okamoto T, Miyanishi K, Sato T, Araki H, Iyama S, Abe S, Murase K, Takimoto R, Nagakura H, Hareyama M, Kato J, Niitsu Y: A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. Cancer Chemother Pharmacol 2006; 58: 570-576.
21. Yoshinaga K, Niikura H, Ogawa Y, Nemoto K, Nagase S, Takano T, Ito K, Yaegashi N: Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2007; 104: 36-40.
22. Yokoyama Y, Takano T, Nakahara K, Shoji T, Sato H, Yamada H, Yaegashi N, Okamura K, Kurachi H, Sugiyama T, Tanaka T, Sato A, Tase T, Mizunuma H: A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study. Oncol Rep 2008; 19: 1551-1556.
23. Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M: Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 1990; 52: 15-24.
24. Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N: Phase I study and pharmacological analysis of cis- diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5- day continuous intravenous infusion. Cancer Res 1991; 51: 1472-1477.
25. Toita T, Kodaira T, Shinoda A, Uno T, Akino Y, Mitsumori M, Teshima T: Patterns of radiotherapy practice for patients with cervical cancer (1999-2001): patterns of care study in Japan. Int J Radiat Oncol Biol Phys 2008; 70: 788-794.
26. Teshima T, Inoue T, Ikeda H, Miyata Y, Nishiyama K, Inoue T, Murayama S, Yamasaki H, Kozuka T: High-dose rate and lowdose rate intracavitary therapy for carcinoma of the uterine cervix: final results of Osaka University Hospital. Cancer 1993; 72: 2409-2414. (Pubitemid 23299606)
27. Hareyama M, Sakata K, Oouchi A, Nagakura H, Shido M, Someya M, Koito K: High-doserate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer 2002; 94: 117-124.
28. Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, Khorprasert C, Rojpornpradit P, Chottetanaprasith T, Srisuthep A, Suriyapee S, Jumpangern C, Tresukosol D, Charoonsantikul C: Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys 2004; 59: 1424-1431.
29. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
30. Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D: Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002; 20: 891-893.
31. Niibe Y, Tsunoda S, Jobo T, Imai M, Matsuo K, Matsunaga K, Unno N, Hayakawa K: Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501) - initial analysis. Eur J Gynaecol Oncol 2008; 29: 222-224.
32. Kodama J, Takemoto M, Seki N, Nakamura K, Hongo A, Kanazawa S, Hiramatsu Y: Phase I study of weekly nedaplatin and concurrent pelvic radiotherapy as adjuvant therapy after radical surgery for cervical cancer. Int J Gynecol Cancer 2008; 18: 1037-1041.
33. Toita T, Moromizato H, Ogawa K, Kakinohana Y, Maehama T, Kanazawa K, Murayama S: Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer. Gynecol Oncol 2005; 96: 665-670.
34. Chung YL, Jian JJ, Cheng SH, Hsieh CI, Tan TD, Chang HJ, Hung CF, Horng CF, Soong T, Tsou MH: Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study. Gynecol Oncol 2005; 97: 126-135.
35. Chen SW, Liang JA, Hung YC, Yeh LS, Chang WC, Lin WC, Yang SN, Lin FJ: Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications. Int J Radiat Oncol Biol Phys 2006; 66: 1370-1377.
36. Pötter R, Dimopoulos J, Bachtiary B, Sissolak G, Klos B, Rheinthaller A, Kirisits C, Knocke-Abulesz TH: 3D conformal HDRbrachy- and external beam therapy plus simultaneous cisplatin for high-risk cervical cancer: clinical experience with 3 year follow- up. Radiother Oncol 2006; 79: 80-86.
37. Novetsky AP, Einstein MH, Goldberg GL, Hailpern SM, Landau E, Fields AL, Mutyala S, Kalnicki S, Garg M: Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer. Gynecol Oncol 2007; 105: 635-640.
38. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 358: 781-786.